|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN UROLOGICAL ASSOCIATION ANNUAL MEETING |
|
|
|
|
|
|
| Prostate Cancer: Advanced (Including Drug Therapy) I - 07:00-09:00 CST |
|
|
|
|
PD01-03: Third Interim Analysis of the DARolutamide ObservationaL (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer
Presented By: TBD
|
|
|
|
|
PD01-04: Efficacy of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer with a Germline or Somatic BRCA Mutation in the PROpel Trial
Presented By: Neal Shore, MD, FACS
|
|
|
|
|
PD01-06: Prostate-Specific Antigen Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis
Presented By: Stephen Freedland, MD
|
|
|
|
|
| Plenary Friday Morning - 07:30-11:30 CST |
|
|
|
|
Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: Pivotal Results from BOND-003: A Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented By: Mark Tyson, II, MD, MPH
|
|
|
|
|
Paradigm-Shifting, Practice-Changing Clinical Trials in Urology: Efficacy of [177Lu]Lu-PSMA-617 Versus ARPI Change in Taxane-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer by Pre-Randomization ARPI (PSMAfore)
Presented By: Xiao Wei, MD, MAS
|
|
|
|
|
| Plenary Friday Afternoon - 13:00-16:30 CST
|
|
|
|
|
State-of-the-Art Lecture: Advances in Molecular Imaging for Renal Tumors
Presented By: Mohamad Allaf, MD
|
|
|
|
|
| MP16: Bladder Cancer: Non-Invasive I - 13:00-15:00 - CST |
|
|
|
|
MP16-03: N-803 plus BCG Complete Response Rate in NMIBC CIS Subjects: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032)
Presented By: Patrick Soon-Shiong, MD
|
|
|
|
|
| Saturday, May 4, 2024 |
| PD18: Kidney Cancer: Advanced (including Drug Therapy) II - 07:00-09:00 CST |
|
|
|
|
PD18-04: Survival is Dramatically Improved for mRCC Patients with Sarcomatoid Features who are Treated with Cytoreductive Nephrectomy and Immune Checkpoint Inhibitors Regardless of Treatment Sequence
Presented By: Daniel Shapiro, MD
|
|
|
|
|
PD18-08: Tumor Size Reduction (≥10% ) Resulting from Pre-Surgical Systemic Therapy Predicts Improved Survival Following Cytoreductive Nephrectomy
Presented By: Daniel Shapiro, MD
|
|
|
|
|
PD18-12: Outcomes of minimally invasive nephrectomy following immune-checkpoint inhibitor therapy: Data from a multicenter study
Presented By: Alireza Ghoreifi, MD
|
|
|
|
|
PD30: Bladder Cancer: Non-Invasive II - 13:00-15:00 CST
|
PD27-12: Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer
Presented By: Yair Lotan, MD
PD30-09: Response to Primary Chemoablation With UGN-102 in Patients with New or Recurrent LG IR NMIBC: Post-hoc Analysis of the ATLAS Trial
Presented By: William Huang, MD
|
|
|
|
|
|
|
|
|
|
| MP41: Prostate Cancer: Markers I - 15:30-17:30 CST
|
|
|
|
|
MP41-14: High Decipher Score Defines the Subgroup Most at Risk of Metastatic Progression Among Patients with Lower Grade Tumors Classified as NCCN High-Risk Based on Elevated Prostate-Specific Antigen Level Alone
Presented By: David Han, MD
|
|
|
|
|
| Sunday, May 5, 2024
|
| MP49: Prostate Cancer: Detection & Screening IV - 07:00-09:00 CST |
|
|
|
|
MP49-09: Decipher® Predicts Clinically Significant Upgrading on Final Radical Prostatectomy Pathology
Presented By: John Sheng, MD
|
|
|
|
|
| PD42: Prostate Cancer: Markers II - 09:30 - 11:00 CST |
|
|
|
|
PD42-01: Variation in Prostate Cancer Genomic Subtypes Across Prostate Magnetic Resonance Imaging PIRADS Scores and Race
Presented By: Nimrod Barashi Goza, MD
|
|
|
|
|
PD42-11: Development and Validation of a Multimodal Artificial Intelligence (MMAI)-Derived Digital Pathology-Based Biomarker Predicting Metastasis for Radical Prostatectomy Patients with Biochemical Recurrence in NRG/RTOG Trials
Presented By: Todd Morgan, MD
|
|
|
|
|
| PD48: Bladder Cancer Non-invasive III - 13:00 - 15:00 CST |
|
|
|
|
PD48-05: Use of Blue Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes in an Equal Access setting: A Propensity Scored Matched Analysis
Presented By: Sanjay Das, MD
|
|
|
|
|
Clinical Trials in Progress - 10:00 - 12:00 CST
|
BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Presented By: Mark Tyson II, MD, MPH
PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor
Presented By: Robert Svatek, MD, MSCI
|
|
|
|
|
|
|
|
|
|
A Phase II Prospective, Open-Label, Multi-Center, Single Arm Study of Sasanlimab plus Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Patients. SSANTROP (APRO07-2022)
Presented By: Oscar Rodríguez Faba, Ph.D.
|
|
|
|
|
| AUA-IBCG Bladder Cancer Forum - 14:00-17:00 CST |
|
|
|
|
Role of Urinary Markers in Surveillance of NMIBC Patients
Presented By: Kamal Pohar, MD, Yair Lotan, MD, and Kelly Bree, MD
|
|
|
|
|
Optimal TURBT: Do Skilled Urologists Really need to Perform reTUR for all HG Patients?
Presented By: Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), Neal Shore, MD, FACS, and Badrinath Konety, MD, MBA
|
|
|
|
|
Management of Recurrent LG Intermediate Risk Bladder Tumors
Presented By: Sarah Psutka, MD, Robert S Svatek, MD, MSCI, and Paramananthan Mariappan, MD, Ph.D.
|
|
|
|
|
Very High-Risk NMIBC with Variant Histology
Presented By: Joan Palou MD, PhD, FEBU, FRCS (Glas), and Michael Cookson, MD, MMHC
|
|
|
|
|
BCG Unresponsive Disease: How Much Risk Can My Patient Tolerate?
Presented By: Sima Porten, MD, MPH, and Alexandre Zlotta MD, Ph.D., FRCSC
|
|
|
|
|
Can we Settle the Debate on PLND in Radical Cystectomy?
Presented By: Sia Daneshmand, MD, Seth Lerner, MD, FACS, and John Taylor, MD, MS
|
|
|
|
|
| Can I use Markers and Imaging to Avoid Local Consolidation for Patient who is cT0 after Neoadjuvant Chemo or IO?Presented By: Arnulf Stenzl, MD, Stephen Williams, MD, MS, FACS, and Petros Grivas, MD, Ph.D.
|
|
|
|
|
First Line Therapy for Locally Advanced/Metastatic UC in 2024
Presented By: Andrea Necchi, MD, Shilpa Gupta, MD, and Karima Oualla, MD, MSc
|
|
|
|
|
| MP60: Prostate Cancer: Advanced (including Drug Therapy) III - 15:30-17:30 CST |
|
|
|
|
MP60-11: Evaluation of Response to 177Lu-PSMA-617 by Site Specific Disease in Metastatic Castrate-Resistant Prostate Cancer
Presented By: Ahmed Mahmoud, Ph.D.
|
|
|
|
|
MP60-18: Darolutamide Real-World Doublet and Triplet Utilization in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): US Community Urology Setting
Presented By: Benjamin H. Lowentritt, MD, FACS
|
|
|
|
|
| Monday, May 6, 2024
|
| MP71: Bladder Cancer: Non-Invasive IV - 09:30-11:30 CST
|
|
|
|
|
MP71-18: Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern HD 4K Equipment: An Analysis of Pivotal Trial and Real-World Data in China
Presented By: Hailong Hu, Ph.D.
|
|
|
|
|
